8月19日，安必平今日收盘31.62元，上涨2.80%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到1322.28倍，总市值29.59亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.49倍，行业中值40.19倍，安必平排名 第122位。 股东方面，截至2025年3月31日，安必平股东户数10309户，较上次增加4393户，户均持股市值35.28万 元，户均持股数量2.76万股。 广州安必平医药科技股份有限公司的主营业务是肿瘤筛查及诊断试剂、自动化设备及辅助诊断人工智能 软件等。公司的主要产品是肿瘤筛查及诊断试剂、自动化设备、辅助诊断人工智能软件。 最新一期业绩显示，2025年一季报，公司实现营业收入7254.35万元，同比-28.51%；净利 润-11064498.81元，同比-238.49%，销售毛利率61.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安必平1322.28138.962.3829.59亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.9559.18亿1九安医疗11.6511.780.92196.5 ...

8月15日，安必平今日收盘30.22元，上涨1.99%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到1263.74倍，总市值28.28亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，安必平排名 第122位。 最新一期业绩显示，2025年一季报，公司实现营业收入7254.35万元，同比-28.51%；净利 润-11064498.81元，同比-238.49%，销售毛利率61.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安必平1263.74132.812.2728.28亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8 ...

股东方面，截至2025年3月31日，安必平股东户数10309户，较上次增加4393户，户均持股市值35.28万 元，户均持股数量2.76万股。 8月8日，安必平今日收盘31.05元，下跌6.87%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到1298.45倍，总市值29.05亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.70倍，行业中值39.08倍，安必平排名 第122位。 最新一期业绩显示，2025年一季报，公司实现营业收入7254.35万元，同比-28.51%；净利 润-11064498.81元，同比-238.49%，销售毛利率61.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安必平1298.45136.452.3329.05亿行业平均 55.7051.864.84117.31亿行业中值39.0838.492.8857.46亿1九安医疗11.1411.270.88188.05亿2英科医疗 15.5716.791.39246.03亿3山东药玻16.0616.111.85151.90亿4振德医疗16.3115.371.0459.21亿5新华医疗 1 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anbiping, a company in the medical device industry, which is currently facing significant challenges reflected in its high PE ratio and declining revenues [1][2] - Anbiping's closing stock price is 31.75 yuan, with a PE ratio of 1327.72, significantly higher than the industry average of 54.56 and the median of 37.54 [1][2] - The company's total market capitalization is 2.971 billion yuan, ranking it 122nd in the industry based on PE ratio [1][2] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1]

Company Overview - Anbiping's closing price on July 11 was 29.62 yuan, up 3.82%, with a rolling PE ratio of 1238.65, marking a new low in 22 days, and a total market capitalization of 2.771 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.0645 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Industry Comparison - The average PE ratio for the medical device industry is 52.06, with a median of 37.22, placing Anbiping at the 122nd position in the industry ranking [1] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.97 for Sanxin Medical [2]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of July 8, Anbiping's closing price was 29.01 yuan, with a PE ratio of 1213.14, and a total market capitalization of 2.714 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49% [1] - The gross profit margin for Anbiping stands at 61.97% [1]

Company Overview - Anbiping's closing price on July 2 was 28.41 yuan, down 3.83%, with a rolling PE ratio of 1188.05 times and a total market value of 2.658 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing Anbiping at the 122nd position in the industry ranking [1][2] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.76 times for Antu Biology, indicating a substantial valuation gap [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - Anbiping's closing stock price on June 27 was 28.66 yuan, reflecting a 3.54% increase, with a rolling PE ratio of 1198.50 times and a total market capitalization of 2.682 billion yuan [1] - The average PE ratio for the medical device industry is 49.70 times, with a median of 35.80 times, positioning Anbiping at the 122nd rank within the industry [1][2] Group 2 - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business of Anbiping includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, Anbiping reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1]

Core Viewpoint - Anbiping's stock price closed at 30.88 yuan, down 4.28%, with a rolling PE ratio of 1291.34 times, significantly higher than the industry average [1] Company Summary - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest performance report for Q1 2025 shows a revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Industry Summary - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Anbiping at the 121st position in the industry ranking [2] - The total market capitalization of Anbiping is 2.889 billion yuan [2] - As of Q1 2025, there are 7 institutions holding shares in Anbiping, with a total holding of 26.54 million shares valued at 949.7 million yuan [1]